ProMIS Neurosciences Issues Chairman’s Memorandum
December 16, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
ProMIS Neurosciences Shareholders Approve Special Resolution
December 02, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development...
A Second Independent Proxy Advisor, ISS, Recommends Promis Neurosciences Shareholders Vote for the Share Consolidation
November 17, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. ...
ProMIS Neurosciences Announces Third Quarter 2021 Results
November 12, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
Glass Lewis Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation at the Upcoming Special Meeting
November 02, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO...
ProMIS Neurosciences Announces Update to Senior Management Team
October 22, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors
October 22, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Files Special Meeting Proxy Material
October 21, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. TORONTO...
ProMIS Neurosciences Announces Special Shareholder Meeting
October 07, 2021 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development...
ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021
September 15, 2021 07:30 ET
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...